Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Dae Woong Kim

Physician Assistant Queen Creek, AZ Physician Assistant

NPI 1386132652 CMS profile 10601366

21321 E Ocotillo Rd Ste 133, Queen Creek, AZ 85142

Open in the dashboard

General payments

$3,442

179 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dae Woong Kim of Queen Creek, AZ is reported in the CMS Open Payments database as having received $3,442 across 179 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,109 65
2024 General $1,379 68
2023 General $539 33
2022 General $212 5
2021 General $203 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dae Woong Kim
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Dae Woong Kim were reported at $1,109. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Dae Woong Kim Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $203 $132 $37–$438 $132
2022 $212 $155 $48–$522 $149
2023 $539 $167 $52–$557 $160
2024 $1,379 $178 $55–$600 $164
2025 $1,109 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,037 66 payments
  2. AstraZeneca Pharmaceuticals LP $671 13 payments
  3. Lilly USA, LLC $373 24 payments
  4. Novo Nordisk Inc $325 19 payments
  5. Pfizer Inc. $247 18 payments
  6. Lucid Diagnostics Inc. $107 3 payments
  7. GlaxoSmithKline, LLC. $105 5 payments
  8. Astellas Pharma US Inc $89 4 payments
  9. Phathom Pharmaceuticals, Inc. $66 4 payments
  10. Biohaven Pharmaceuticals, Inc. $54 2 payments
  11. Other $369 21 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,433 178 payments
  2. Education $9 1 payment
Products named General payments · program years 2021–2025
  1. QULIPTA $516 30 payments
  2. UBRELVY $380 25 payments
  3. MOUNJARO $354 21 payments
  4. FARXIGA $324 4 payments
  5. BREZTRI $254 5 payments
  6. NURTEC ODT $247 18 payments
  7. VRAYLAR $245 21 payments
  8. AIRSUPRA $233 4 payments
  9. ZAVZPRET $216 16 payments
  10. Ozempic $203 11 payments
  11. Other $1,552 86 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 68 drugs

Part D claims

2,070

Median for Physician Assistant: 241

Drug cost

$169,227

Median for Physician Assistant: $4,110

Branded share of claims

21.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 77 $89,323
Ozempic Semaglutide Brand 32 $31,781
Farxiga Dapagliflozin Propanediol Brand 11 $16,838
Progesterone Progesterone, Micronized Brand 40 $2,085
Insulin Lispro Kwikpen U-100 Insulin Lispro Brand 14 $1,950
Testosterone Cypionate Generic 53 $1,908
Gabapentin Generic 43 $1,373
Ezetimibe Generic 25 $1,224
Olmesartan Medoxomil Generic 14 $1,116
Atorvastatin Calcium Generic 99 $1,061

The 10 drugs with the highest cost, of 68 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$122,596

Of which drugs: $4,872

Medicare patients

218

Average age 73

Services billed

3,079

102 women, 116 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Chronic kidney disease 43%
Ischemic heart disease 35%
Diabetes 26%
Atrial fibrillation 18%
COPD 18%
Depression 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 15 15 $4,354

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $165
$165 — —
QULIPTA
  • AbbVie, Inc. $159
$159 — —
VRAYLAR
  • AbbVie, Inc. $157
$157 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $152
$152 11 —
MOUNJARO
  • Lilly USA, LLC $151
$151 77 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

179 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record